CDK 4/6 Inhibitor Improves PFS for Patients with HR+/HER- Breast Cancer

Hope S. Rugo, MD of the UCSF Medical Center discusses the state of CDK 4/6 Inhibitors for Patients with HR+/HER- Breast Cancer